Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964934 · ClinicalTrials.gov registry record · Phase 3
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
A Phase 3 study of ER-Positive HER2-Negative Breast Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 315
- Enrollment target
- 20
- Study locations
NCT04964934 is a Phase 3 study of ER-Positive HER2-Negative Breast Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 315 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT04964934, a Phase 3 study of ER-Positive HER2-Negative Breast Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 315 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
Conditions Studied
Interventions
- DRUG Anastrozole
- DRUG Letrozole
- DRUG AZD9833
- DRUG AZD9833 Placebo
- DRUG Anastrozole placebo
Study Locations (20)
Florida
- Research Site - Fort Myers
- Research Site - Jacksonville
- Research Site - Jacksonville
- Research Site - St. Petersburg
California
- Research Site - Long Beach
- Research Site - San Diego
- Research Site - Santa Rosa
Georgia
- Research Site - Atlanta
- Research Site - Atlanta
- Research Site - Atlanta
Arkansas
- Research Site - Hot Springs
- Research Site - Little Rock
Colorado
- Research Site - Grand Junction
- Research Site - Lone Tree
Indiana
- Research Site - Fort Wayne
- Research Site - Indianapolis
Arizona
- Research Site - Phoenix
Illinois
- Research Site - Park Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2027-11-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04964934
The ClinicalTrials.gov registry entry for NCT04964934 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ER-Positive HER2-Negative Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Anastrozole is the first listed.
NCT04964934 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04964934 about?
NCT04964934 is a clinical study titled "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)". The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal gro...
What is the current status of trial NCT04964934?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 315 participants. The study started on 2021-06-30. Estimated completion is 2027-11-26.
What conditions does trial NCT04964934 study?
This clinical trial studies the following conditions: ER-Positive HER2-Negative Breast Cancer.
What interventions are being tested in trial NCT04964934?
The interventions under investigation include: Anastrozole (DRUG), Letrozole (DRUG), AZD9833 (DRUG), AZD9833 Placebo (DRUG), Anastrozole placebo (DRUG).
Who is sponsoring clinical trial NCT04964934?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04964934 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ER-Positive HER2-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.